Intellia says FDA accepts lonvo-z BLA for hereditary angioedema, grants priority review

• FDA accepted Intellia’s BLA for lonvoguran ziclumeran (lonvo-z) in hereditary angioedema, granting Priority Review.
• PDUFA target action date set for March 10, 2027.
• FDA does not currently plan to convene an advisory committee for the application.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intellia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609080800PRIMZONEFULLFEED9822304) on September 08, 2026, and is solely responsible for the information contained therein.